Table 1.
Demographics.
| Age, median (range) | 58 (30–83) |
| Sex | |
| Female | 11/38 (29%) |
| Male | 27/38 (71%) |
| ECOG performance status | |
| ECOG PS 0 | 27/38 (71%) |
| ECOG PS 1 | 11/38 (29%) |
| LDH at study entry | |
| LDH ≤ ULN | 20/38 (53%) |
| LDH > ULN | 18/38 (47%) |
| LDH 1–2X ULN | 15/38 (39%) |
| LDH ≥ 2X ULN | 3/38 (8%) |
| Stage at study entry | |
| Unresectable stage IIIC | 0/38 (0%) |
| Stage IV M1a | 9/38 (24%) |
| Stage IV M1b | 9/38 (24%) |
| Stage IV M1c | 15/38 (39%) |
| Stage IV M1d | 5/38 (13%) |
| No. of prior systemic therapies | |
| 0 | 19/38 (50%) |
| 1 | 8/38 (21%) |
| 2 | 9/38 (24%) |
| 3 | 2/38 (5%) |
| Prior immune checkpoint inhibition | |
| in patients with prior Rx | 19/19 (100%) |
| Baseline tumor size | |
| < 5 cm | 16 (42%) |
| ≥ 5 cm | 20 (52%) |
| N/A | 2 (6%) |
| Brain metastases | 5/38 (13%) |
Abbreviation: Rx, treatment.